NEW YORK, NY / ACCESSWIRE / May 1, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on BioLineRx Ltd. (NASDAQ: BLRX) is a clinical stage biopharmaceutical development company, focused on oncology and immunology. The Company in-licenses novel compounds, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.
Recently, the company reported its financial results for the year ended December 31, 2018 and provided a corporate update.
Review the milestones achieved in 2018 and potential catalyst for 2019 READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/biolinerx-2/
Get a broader look at the BLRX pipeline and recent stem-cell developments READ MORE
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: [email protected]
SOURCE: Traders News Source